BRIEF-Intercept Pharma says patients treated with Ocaliva UDCA had significantly improved estimated liver transplant-free survival

* Of 216 randomized patients in poise trial, 93% continued receiving ursodeoxycholic acid (UDCA) upon initiating ocaliva or placebo
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.